Reply to Letter Regarding Article, “Clinical Significance of High-Molecular Weight Form of Adiponectin in Male Patients With Coronary Artery Disease”

We thank Dr Oda and Dr Watanabe for their comments regarding our paper and we have published an erratum in the Journal (2008; 72: 508).

In the study in question, we reported that total and high-molecular weight adiponectin were equally useful in assessing metabolic risk in patients with coronary artery disease (CAD). We previously reported a reciprocal association of adiponectin and C-reactive protein (CRP) in patients with CAD. Therefore, although there are some limitations, both adiponectin and high-sensitivity CRP are beneficial for evaluating CAD risk.

References

Noriyuki Komura, MD
Shinji Kihara, MD
Tohru Funahashi, MD
Department of Metabolic Medicine,
Graduate School of Medicine,
Osaka University,
Suita, Japan